Tag: <span>RADICAVA</span>

Home / RADICAVA
Post

FIRST FDA-APPROVED TREATMENT FOR ALS IN 22 YEARS NOW AVAILABLE IN U.S.

JERSEY CITY, N.J., Aug. 8, 2017 – Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is now available for treatment in the United States. RADICAVA, the first FDA-approved ALS treatment option in more than 20 years,...